Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Center for International Blood and Marrow Transplant Research
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University Health Network, Toronto
BeOne Medicines
GeoVax, Inc.
Center for International Blood and Marrow Transplant Research
Alliance for Clinical Trials in Oncology
University of Wisconsin, Madison
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Celgene
BeOne Medicines
Washington University School of Medicine
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Hospital of Philadelphia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
National Cancer Institute (NCI)
University of Alabama at Birmingham
National Cancer Institute (NCI)
Weill Medical College of Cornell University
University Hospital Southampton NHS Foundation Trust
Chinese PLA General Hospital
Memorial Sloan Kettering Cancer Center
Takeda
City of Hope Medical Center
University of Chicago
Eastern Cooperative Oncology Group
UNC Lineberger Comprehensive Cancer Center